Editas Medicine Inc (NASDAQ:EDIT) insider Katrine Bosley sold 14,995 shares of Editas Medicine stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $34.15, for a total transaction of $512,079.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Katrine Bosley also recently made the following trade(s):
- On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $29.58, for a total transaction of $246,490.14.
- On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $23.64, for a total transaction of $196,992.12.
Editas Medicine Inc (NASDAQ:EDIT) traded down $0.22 on Friday, hitting $33.70. 526,595 shares of the company were exchanged, compared to its average volume of 1,333,454. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. The stock has a market capitalization of $1,500.00 and a P/E ratio of -10.40. Editas Medicine Inc has a one year low of $13.12 and a one year high of $36.00.
Large investors have recently modified their holdings of the business. First Midwest Bank Trust Division purchased a new position in Editas Medicine during the third quarter valued at approximately $1,349,000. Greenwoods Asset Management Ltd purchased a new position in shares of Editas Medicine in the second quarter worth $1,191,000. American Century Companies Inc. purchased a new position in shares of Editas Medicine in the third quarter worth $7,497,000. Bank of New York Mellon Corp lifted its holdings in shares of Editas Medicine by 123.8% in the second quarter. Bank of New York Mellon Corp now owns 142,122 shares of the company’s stock worth $2,385,000 after buying an additional 78,632 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Editas Medicine in the second quarter worth $285,000. 65.70% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have recently commented on EDIT. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. ValuEngine cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Editas Medicine has a consensus rating of “Hold” and an average price target of $26.73.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.